Incidence and progression to cirrhosis of new hepatitis C virus infections in persons living with human immunodeficiency virus

M. Puoti; P Lorenzini; A. Lepri Cozzi; A Gori; C. Mastroianni; G. Rizzardini; G. Mazzarello; A Antinori; A. d'Arminio Monforte; E Girardi; Icona Foundation Study Group; Alessandra Latini; Antonio Cristaudo

doi:10.1016/j.cmi.2016.12.003

Incidence and progression to cirrhosis of new hepatitis C virus infections in persons living with human immunodeficiency virus

M. Puoti, P Lorenzini, A. Lepri Cozzi, A Gori, C. Mastroianni, G. Rizzardini, G. Mazzarello, A Antinori, A. d'Arminio Monforte, E Girardi, Icona Foundation Study Group, Alessandra Latini, Antonio Cristaudo

Istituto S. Maria e S. Gallicano

Research output: Contribution to journal › Article › peer-review

Abstract

OBJECTIVE: To estimate the incidence of hepatitis C virus (HCV) seroconversion and the risk of severe fibrosis/cirrhosis in HCV seroconverters among persons with human immunodeficiency virus (HIV) infection.

METHODS: We analysed data on 4059 persons with HIV enrolled in a cohort study in Italy.

RESULTS: Incidence rate of seroconversion was 0.6/100 person-years overall, and drug users and men-who-have-sex-with-men were at highest risk. The cumulative risk of progression to severe fibrosis/cirrhosis was 30% by 10 years after seroconversion.

CONCLUSIONS: New HCV infections have a rapidly progressive course in this population. Persons with HIV and HCV superinfection should be prioritized for treatment with anti-HCV direct-acting antivirals.

Original language	English
Pages (from-to)	267.e1-267.e4
Journal	Clinical Microbiology and Infection
Volume	23
Issue number	4
Early online date	Dec 9 2016
DOIs	https://doi.org/10.1016/j.cmi.2016.12.003
Publication status	Published - Apr 2017

Keywords

Journal Article

Access to Document

10.1016/j.cmi.2016.12.003

Cite this

Puoti, M., Lorenzini, P., Lepri Cozzi, A., Gori, A., Mastroianni, C., Rizzardini, G., Mazzarello, G., Antinori, A., d'Arminio Monforte, A., Girardi, E., Icona Foundation Study Group, Latini, A., & Cristaudo, A. (2017). Incidence and progression to cirrhosis of new hepatitis C virus infections in persons living with human immunodeficiency virus. Clinical Microbiology and Infection, 23(4), 267.e1-267.e4. https://doi.org/10.1016/j.cmi.2016.12.003

Puoti, M, Lorenzini, P, Lepri Cozzi, A, Gori, A, Mastroianni, C, Rizzardini, G, Mazzarello, G, Antinori, A, d'Arminio Monforte, A, Girardi, E, Icona Foundation Study Group, Latini, A & Cristaudo, A 2017, 'Incidence and progression to cirrhosis of new hepatitis C virus infections in persons living with human immunodeficiency virus', Clinical Microbiology and Infection, vol. 23, no. 4, pp. 267.e1-267.e4. https://doi.org/10.1016/j.cmi.2016.12.003

@article{37f53eb37f9041f6944a167b8d99bf31,

title = "Incidence and progression to cirrhosis of new hepatitis C virus infections in persons living with human immunodeficiency virus",

abstract = "OBJECTIVE: To estimate the incidence of hepatitis C virus (HCV) seroconversion and the risk of severe fibrosis/cirrhosis in HCV seroconverters among persons with human immunodeficiency virus (HIV) infection.METHODS: We analysed data on 4059 persons with HIV enrolled in a cohort study in Italy.RESULTS: Incidence rate of seroconversion was 0.6/100 person-years overall, and drug users and men-who-have-sex-with-men were at highest risk. The cumulative risk of progression to severe fibrosis/cirrhosis was 30% by 10 years after seroconversion.CONCLUSIONS: New HCV infections have a rapidly progressive course in this population. Persons with HIV and HCV superinfection should be prioritized for treatment with anti-HCV direct-acting antivirals.",

keywords = "Journal Article",

author = "M. Puoti and P Lorenzini and {Lepri Cozzi}, A. and A Gori and C. Mastroianni and G. Rizzardini and G. Mazzarello and A Antinori and {d'Arminio Monforte}, A. and E Girardi and {Icona Foundation Study Group} and Alessandra Latini and Antonio Cristaudo",

year = "2017",

month = apr,

doi = "10.1016/j.cmi.2016.12.003",

language = "English",

volume = "23",

pages = "267.e1--267.e4",

journal = "Clinical Microbiology and Infection",

issn = "1198-743X",

publisher = "Elsevier B.V.",

number = "4",

}

TY - JOUR

T1 - Incidence and progression to cirrhosis of new hepatitis C virus infections in persons living with human immunodeficiency virus

AU - Puoti, M.

AU - Lorenzini, P

AU - Lepri Cozzi, A.

AU - Gori, A

AU - Mastroianni, C.

AU - Rizzardini, G.

AU - Mazzarello, G.

AU - Antinori, A

AU - d'Arminio Monforte, A.

AU - Girardi, E

AU - Icona Foundation Study Group

AU - Latini, Alessandra

AU - Cristaudo, Antonio

PY - 2017/4

Y1 - 2017/4

N2 - OBJECTIVE: To estimate the incidence of hepatitis C virus (HCV) seroconversion and the risk of severe fibrosis/cirrhosis in HCV seroconverters among persons with human immunodeficiency virus (HIV) infection.METHODS: We analysed data on 4059 persons with HIV enrolled in a cohort study in Italy.RESULTS: Incidence rate of seroconversion was 0.6/100 person-years overall, and drug users and men-who-have-sex-with-men were at highest risk. The cumulative risk of progression to severe fibrosis/cirrhosis was 30% by 10 years after seroconversion.CONCLUSIONS: New HCV infections have a rapidly progressive course in this population. Persons with HIV and HCV superinfection should be prioritized for treatment with anti-HCV direct-acting antivirals.

AB - OBJECTIVE: To estimate the incidence of hepatitis C virus (HCV) seroconversion and the risk of severe fibrosis/cirrhosis in HCV seroconverters among persons with human immunodeficiency virus (HIV) infection.METHODS: We analysed data on 4059 persons with HIV enrolled in a cohort study in Italy.RESULTS: Incidence rate of seroconversion was 0.6/100 person-years overall, and drug users and men-who-have-sex-with-men were at highest risk. The cumulative risk of progression to severe fibrosis/cirrhosis was 30% by 10 years after seroconversion.CONCLUSIONS: New HCV infections have a rapidly progressive course in this population. Persons with HIV and HCV superinfection should be prioritized for treatment with anti-HCV direct-acting antivirals.

KW - Journal Article

U2 - 10.1016/j.cmi.2016.12.003

DO - 10.1016/j.cmi.2016.12.003

M3 - Article

C2 - 27956268

VL - 23

SP - 267.e1-267.e4

JO - Clinical Microbiology and Infection

JF - Clinical Microbiology and Infection

SN - 1198-743X

IS - 4

ER -

Incidence and progression to cirrhosis of new hepatitis C virus infections in persons living with human immunodeficiency virus

Abstract

Keywords

Access to Document

Fingerprint

Cite this